MediciNova Inc. (MNOV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.47+0.37 (+5.21%)
At close: 4:00 PM EDT

7.47 -0.00 (-0.02%)
After hours: 4:17 PM EDT

People also watch:
OPXACYTKTTHICYCCIDRA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.08
Prev Close7.10
Bid5.19 x 100
Ask7.49 x 1500
Day's Range7.08 - 7.49
52wk Range2.62 - 10.16
1y Target EstN/A
Market Cap257.5M
P/E Ratio (ttm)-20.47
Beta-0.22
Volume34,174
Avg Vol (3m)64,301
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Options on MediciNova Common Stock Listed on CBOE

    LA JOLLA, Calif., Sept. 25, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the Chicago Board ...

  • MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
    Zacks Small Cap Research2 months ago

    MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16

    MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 is an anti-inflammatory drug that has been used for over 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.

  • GlobeNewswire2 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis

    LA JOLLA, Calif., July 24, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that it has received ...